Why the study?
Do various natural products, drugs, and delivery systems protect against doxorubicin-induced toxicity?
Do various natural products, drugs, and delivery systems protect against doxorubicin-induced toxicity?
Answers are grounded in this paper and cite their sources.
This review summarizes recent advances in strategies to mitigate doxorubicin-induced toxicity, which is a major dose-limiting factor in its clinical use.
Anthracycline antibiotics are among the most effective and commonly used anticancer drugs. Unfortunately, their clinical use is restricted by dose-dependent toxicity. Doxorubicin is an anthracycline antibiotic and cytotoxic (antineoplastic) agent. It is commonly used against ovarian, breast, lung, uterine and cervical cancers, Hodgkin's disease, soft tissue and primary bone sarcomas, as well against in several other cancer types. It has been shown that free radicals are involved in doxorubicin-induced toxicity. Doxorubicin causes the generation of free radicals and the induction of oxidative stress, associated with cellular injury. This review illustrates recent applications of different natural products, drugs, drug delivery systems, and approaches for protection against doxorubicin-induced toxicity (2006-present).
No takes yet. Share an insight, caveat, or question.
Injac et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: